logo

India Insulin Drug And Delivery Device Market Size (2024 - 2029)

The India Insulin Drug and Delivery Device Market is anticipated to experience growth over the forecast period, driven by the increasing prevalence of diabetes, which has become a significant public health concern in the country. The market's expansion is influenced by the rising adoption of advanced technologies and the need for effective diabetes management, particularly in the context of the heightened risks associated with COVID-19. As diabetes continues to affect a substantial portion of the Indian population, including a growing number in rural areas, the demand for insulin drugs and delivery devices is expected to rise, contributing to the market's growth trajectory.

Home Market Analysis Healthcare Research Medical Devices Research India Insulin Drug And Delivery Device Market Market Size

Market Size of India Insulin Drug And Delivery Device Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
India Insulin Drug And Delivery Device Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR > 1.00 %

Major Players

India Insulin Drug And Delivery Device Market Major Players

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

India Insulin Drug And Delivery Device Market Analysis

India's Insulin Drug and Delivery Device Market is expected to register a CAGR of more than 1% and reach a value of about USD 2.4 billion over the forecast period.

Diabetes was one of the most prominent risk factors for a severe COVID-19 course. This risk was assumed to be influenced by several diabetes-related variables, including advanced age, hyperglycemia, and underlying illnesses (hypertension, cardiovascular disease, chronic renal disease, and obesity). Diabetes was quickly identified as a risk factor for unfavorable outcomes during the COVID-19 pandemic, making diabetes control or delay more important than ever.

Diabetes mellitus, or diabetes in general, is characterized by excessive blood sugar levels. Type 1 diabetes, also known as insulin-dependent diabetes mellitus, is caused by a complete lack of insulin. Type 2 diabetes mellitus is a disease in which the body either produces insufficient insulin or is unable to utilize the insulin that it does generate. Diabetes type 2 is regarded as a lifestyle disease. Sugary sweets are an integral part of Indian culture, as well as historical customs and religious events. According to an article published in "THE HINDU," one in every six diabetics worldwide comes from India. According to data, the country has an estimated 80 million diabetics, ranking second in the globe. Diabetes affects more than half of Indians at some time in their life, making it a serious public health concern. In rural India, the prevalence of type 2 diabetes is also rising. This pushes the market and boosts the rate of adoption of new and sophisticated technology.

India Insulin Drug And Delivery Device Industry Segmentation

Human insulin is a medication of the hormone class. Human insulin is used instead of the insulin that the body normally generates. It aids in the transport of blood sugar to various physiological tissues, where it is utilized as an energy source. It also inhibits the liver from producing extra sugar. India's insulin drug and delivery device market is segmented into type (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins), device type (insulin pens, insulin pumps, insulin syringes, and jet injectors). The report offers the value (in USD million) and volume (in Units million) for the above segments.

Insulin Drugs
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Insulin Device
Insulin Pumps
Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens
Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Need A Different Region Or Segment?
Customize Now

India Insulin Drug And Delivery Device Market Size Summary

The insulin drug and delivery device market in India is poised for growth, driven by the increasing prevalence of diabetes, which affects a significant portion of the population. The market is characterized by a strong demand for insulin medications and delivery devices, as there are no viable alternatives. The introduction of biosimilar insulin products and advancements in insulin delivery technologies, such as insulin pumps, are expected to enhance market growth. These pumps offer benefits over traditional delivery systems, including more precise insulin administration and reduced discomfort. The market is further bolstered by the rise in suppliers, research and development activities, and technological innovations, alongside favorable reimbursement conditions and increased awareness programs.

The growing diabetes population in India, influenced by lifestyle factors and dietary habits, underscores the importance of effective diabetes management solutions. Digital health technologies and applications are playing a crucial role in facilitating diabetes self-management and improving treatment outcomes. The market is highly consolidated, with major global players like Novo Nordisk, Sanofi, Eli Lilly, and others holding significant market shares. Recent collaborations and product launches, such as Sanofi's marketing authorization for Soliqua and Glenmark's launch of Lobeglitazone, highlight the dynamic nature of the market. These developments, coupled with strategic partnerships and mergers, are strengthening the market presence of key players and driving the adoption of advanced insulin therapy solutions.

Explore More

India Insulin Drug And Delivery Device Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Insulin Drugs

      1. 2.1.1 Basal or Long Acting Insulins

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Tresiba (Insulin Degludec)

        5. 2.1.1.5 Basaglar (Insulin Glargine)

      2. 2.1.2 Bolus or Fast Acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.1.2.2 Humalog (Insulin Lispro)

        3. 2.1.2.3 Apidra (Insulin Glulisine)

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Biosimilar Insulins

        1. 2.1.4.1 Insulin Glargine Biosimilars

        2. 2.1.4.2 Human Insulin Biosimilars

      5. 2.1.5 Insulin combinations

        1. 2.1.5.1 NovoMix (Biphasic Insulin Aspart)

        2. 2.1.5.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 2.1.5.3 Xultophy (Insulin Degludec and Liraglutide)

    2. 2.2 Insulin Device

      1. 2.2.1 Insulin Pumps

        1. 2.2.1.1 Insulin Pump Devices

        2. 2.2.1.2 Insulin Pump Reservoirs

        3. 2.2.1.3 Insulin Infusion sets

      2. 2.2.2 Insulin Pens

        1. 2.2.2.1 Cartridges in reusable pens

        2. 2.2.2.2 Disposable insulin pens

      3. 2.2.3 Insulin Syringes

      4. 2.2.4 Insulin Jet Injectors

India Insulin Drug And Delivery Device Market Size FAQs

The India Insulin Drug And Delivery Device Market is projected to register a CAGR of greater than 1% during the forecast period (2024-2029)

Novo Nordisk, Sanofi, Eli Lilly, Medtronics and Roche are the major companies operating in the India Insulin Drug And Delivery Device Market.

India Insulin Drug And Delivery Device Market Report Snapshots

India Insulin Drug And Delivery Device Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)